Cargando…

Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells

The aim of the present study was to investigate the cytotoxic activity of cytokine-induced killer (CIK) cells targeted by an epidermal growth factor receptor (EGFR)/CD3 bispecific antibody (BsAb) to the gastric cancer cell line SGC7901. A BsAb was constructed by chemically cross-linking a monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHANG, LIN, HOU, YANHONG, ZHANG, JIAN, HU, JING, ZHANG, KUNPENG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701003/ https://www.ncbi.nlm.nih.gov/pubmed/23833649 http://dx.doi.org/10.3892/ol.2013.1281

Ejemplares similares

Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
por: He, Qingzhong, et al.
Publicado: (2014)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity.
por: Kroesen, B. J., et al.
Publicado: (1996)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Freedman, Joshua D, et al.
Publicado: (2017)

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
por: Liu, Jie, et al.
Publicado: (2021)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
por: Wang, Zhaoming, et al.
Publicado: (2021)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
por: Yuan, Xin, et al.
Publicado: (2021)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells
por: Wren, Leia, et al.
Publicado: (2012)

Comparison of the proliferation, cytotoxic activity and cytokine secretion function of cascade primed immune cells and cytokine-induced killer cells in vitro
por: LI, GUI-XIN, et al.
Publicado: (2015)

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells
por: Niu, Chao, et al.
Publicado: (2015)

Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer
por: Du, Hansong, et al.
Publicado: (2020)

Cytotoxic Function and Cytokine Production of Natural Killer Cells and Natural Killer T-Like Cells in Systemic Lupus Erythematosis Regulation with Interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2019)

Natural Killer Cell Cytotoxicity and Immunosuppressive Cytokines (IL-10, TGF-β1) in Patients with Gastric Cancer
por: Szkaradkiewicz, Andrzej, et al.
Publicado: (2010)

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023)

The Fyn–ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells
por: Gerbec, Zachary J., et al.
Publicado: (2015)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

Cytokine-induced killer cell/dendritic cell–cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis
por: Wang, Xiang, et al.
Publicado: (2018)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis
por: Liu, Yan, et al.
Publicado: (2017)

A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells
por: Simhadri, Venkateswara R., et al.
Publicado: (2015)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
por: Sun, Yanze, et al.
Publicado: (2023)

Targeting regulatory T cells in cytokine-induced killer cell cultures (Review)
por: TAO, QIANSHAN, et al.
Publicado: (2014)

Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding
por: Wu, Xiaolong, et al.
Publicado: (2020)

Mannan-Binding Lectin Regulates Inflammatory Cytokine Production, Proliferation, and Cytotoxicity of Human Peripheral Natural Killer Cells
por: Zhou, Jia, et al.
Publicado: (2019)

Cytokine-induced killer cells are type II natural killer T cells
por: Gütgemann, Stefan, et al.
Publicado: (2007)

Development of bispecific antibodies in China: overview and prospects
por: Zhang, Jing, et al.
Publicado: (2020)

BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()
por: Xing, Jieyu, et al.
Publicado: (2017)

A dynamic transcriptomic atlas of cytokine-induced killer cells
por: Meng, Mingyao, et al.
Publicado: (2018)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_38d0g5gmr8mvb5ag6ljrd3e3cu